<DOC>
	<DOCNO>NCT00003095</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy breast cancer may damage gene cell . This may lead development secondary cancer . PURPOSE : Pilot study evaluate degree gene damage follow chemotherapy woman stage II stage III breast cancer involve four nine axillary lymph node .</brief_summary>
	<brief_title>S9719 Gene Damage Following Chemotherapy Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate incidence early genetic damage , define presence clonal hematopoiesis use human androgen receptor assay ( HUMARA ) , pretreatment blood bone marrow , apheresis , two sequential post-treatment specimen woman stage II/III breast cancer enrol SWOG-S9623 . II . Detect genetic damage follow dose-intensive adjuvant regimen breast cancer screen presence defective DNA mismatch repair mechanisms loss heterozygosity use microsatellite instability assay . III . Estimate incidence myeloid lymphoid leukemia gene fusion transcript case either HUMARA microsatellite repeat assay positive clonal hematopoiesis . IV . Determine frequency RAS gene mutation ( H- , K- , N-RAS ) follow dose-intensive adjuvant regimen breast cancer . OUTLINE : Prior begin treatment SWOG-9623 , blood sample bone marrow aspirate ( available ) collect patient . Patients randomize autologous peripheral stem cell transplant specimens collect 3 month ( apheresis aliquot blood ) . At 3 12 month complete chemotherapy , blood sample collect patient . Samples collect patient present second malignancy future . DNA collect blood bone marrow sample . Clonality HUMARA locus examine . Microsatellite instability assess multiple chromosomal locus : 7q31 , 5q31 , 17p12 , 8p22 , 11q23 , BAT locus . If HUMARA microsatellite repeat assay positive clonal hematopoiesis , specimen examine myeloid lymphoid leukemia fusion transcript commonly report acute myeloid leukemia 11q23 abnormality . Specimens also examine RAS mutation ( H- , K- , N-RAS ) . Patients receive result genetic test result influence type duration treatment . PROJECTED ACCRUAL : This study accrue 100 patient arm SWOG-9623 , total 200 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must enrol SWOG9623 time registration study , must start treatment Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Adult Sex : Female Menopausal status : Not specify Performance status : See Disease Characteristics Life expectancy : SWOG 0 1 Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Renal : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage III breast cancer</keyword>
</DOC>